korean
red
ginseng
krg
function
food
well
known
keep
good
health
due
antifatigu
immunomodul
activ
howev
data
korean
red
ginseng
prevent
activ
acut
respiratori
ill
ari
studi
conduct
random
doubleblind
placebocontrol
trial
healthi
volunt
clinic
trial
number
primari
efficaci
end
point
number
ari
report
secondari
efficaci
end
point
sever
symptom
number
symptom
durat
ari
total
volunt
enrol
studi
fewer
subject
krg
group
report
contract
least
ari
placebo
group
vs
p
differ
statist
signific
two
group
symptom
durat
subject
experienc
ari
similar
two
group
krg
vs
placebo
vs
p
symptom
score
low
tendenc
krg
group
krg
vs
placebo
vs
p
studi
suggest
krg
may
effect
protect
subject
contract
ari
may
tendenc
decreas
durat
score
ari
symptom
acut
respiratori
ill
ari
selflimit
viral
diseas
caus
mild
symptom
fever
shiver
chill
malais
dri
cough
rhinoviru
coronaviru
common
virus
follow
influenza
viru
adenoviru
influenzaassoci
death
occur
person
age
yr
older
associ
chronic
diseas
vaccin
prevent
influenza
particularli
import
elderli
person
increas
risk
sever
complic
influenza
dietari
supplement
repres
rapidli
grow
segment
market
use
rang
treatment
prevent
common
ill
cancer
treatment
prevent
welldesign
studi
evalu
effect
dietari
supplement
reduct
sever
symptom
durat
upper
respiratori
tract
infect
approv
date
korea
red
ginseng
krg
commerci
avail
old
panax
ginseng
root
steam
unpeel
dri
prepar
light
yellowbrown
light
redbrown
ginseng
manufactur
process
thirteen
kind
activ
ingredi
characterist
red
ginseng
obtain
partli
deglycosyl
saponin
process
conduct
store
red
ginseng
longer
increas
medicin
efficaci
recent
krg
shown
capabl
enhanc
cellmedi
immun
respons
lymphocyt
activ
natur
killer
cell
immunomodul
anticanc
pathway
two
clinic
studi
immun
respons
ginseng
krg
conduct
addit
treatment
pseudomona
aeruginosa
pneumonia
rat
ginseng
found
reduc
bacteri
load
lung
patholog
well
http
increas
immunoglobulin
serum
suggest
antimicrobi
properti
ginseng
due
induct
respons
studi
shown
take
american
ginseng
extract
prophylaxi
influenza
season
older
adult
reduc
incid
acut
respiratori
ill
vaccin
nonvaccin
subject
result
suggest
ginseng
extract
effect
prevent
upper
respiratori
ill
caus
variou
virus
ginseng
well
known
improv
gener
qualityoflif
exhibit
immuonmodul
effect
antidiabet
effect
howev
data
accumul
korean
red
ginseng
prevent
activ
ari
shown
american
ginseng
studi
investig
effect
krg
prevent
activ
ari
administ
krg
placebo
healthi
volunt
week
studi
week
random
doubleblind
placebocontrol
clinic
trial
onset
influenza
season
chonbuk
nation
univers
hospit
fig
subject
respond
met
inclus
criteria
telephon
screen
interview
schedul
baselin
visit
evalu
includ
physic
examin
electrocardiogram
screen
blood
paramet
studi
addit
subject
schedul
screen
visit
within
week
inform
consent
review
sign
random
number
gener
comput
subject
random
code
hidden
subject
research
staff
investig
pharmacist
data
analyz
enrol
subject
schedul
first
visit
subject
randomli
assign
one
two
group
concentr
red
ginseng
n
placebo
n
group
prescript
studi
product
g
time
day
gram
per
day
week
placebo
made
tast
appear
without
princip
ingredi
present
red
ginseng
extract
studi
product
provid
subject
everi
week
intervent
period
week
subject
ask
continu
usual
diet
activ
ask
take
function
food
dietari
supplement
anthropometr
biochem
paramet
vital
sign
measur
intervent
period
group
everi
fourth
week
subject
ask
report
assess
advers
event
chang
train
lifestyl
eat
pattern
assess
complianc
mercuri
thermomet
use
check
bodi
temperatur
place
studi
subject
recruit
octob
novemb
clinic
trial
center
function
food
via
local
newspap
advertis
total
volunt
respond
advertis
prescreen
via
telephon
interview
screen
inclus
exclus
criteria
studi
subject
requir
good
gener
health
yr
age
avoid
confound
effect
vaccin
subject
exclud
vaccin
influenza
within
month
exclus
criteria
studi
hiv
infect
cancer
patient
cardiovascular
diseas
neurolog
psychiatr
diseas
renal
pulmonari
hepat
abnorm
upper
respiratori
infect
within
two
week
prior
studi
activ
tuberculosi
treat
histori
diseas
could
interfer
test
product
imped
absorpt
gastrointestin
diseas
crohn
diseas
gastrointestin
surgeri
append
enterocel
surgeri
includ
particip
clinic
trial
within
past
month
abnorm
liver
function
test
alt
iul
connect
tissu
diseas
patient
multipl
sclerosi
diseas
patient
take
medic
immunosuppress
drug
corticosteroid
warfarin
phenelzin
pentobarbit
haloperidol
cyclosporin
allerg
hypersensit
ginseng
antipsychosi
drug
therapi
within
past
month
laboratori
test
medic
psycholog
condit
deem
investig
interfer
success
particip
studi
histori
alcohol
substanc
abus
pregnanc
breast
feed
judg
respons
physician
local
studi
center
unfit
particip
studi
korean
red
ginseng
produc
process
steam
dri
fresh
ginseng
cultiv
jinangun
korea
standard
red
ginseng
panax
ginseng
ca
meyer
extract
obtain
industri
process
strict
qualiti
control
name
fresh
ginseng
steam
hr
dri
sun
hot
air
ethanol
extract
hr
ethanol
solut
made
highli
concentr
form
give
solid
content
sum
ginsenosid
use
qualiti
control
marker
mgg
placebo
made
maintain
flavor
tast
red
ginseng
extract
also
contain
hop
extract
soybean
oil
red
ginseng
extract
placebo
prepar
cheonjiyang
co
ltd
seoul
korea
ari
defin
follow
symptom
fever
temperatur
cough
sore
throat
nasal
congest
bodi
ach
absenc
known
caus
influenza
primari
efficaci
end
point
frequenc
rate
ari
secondari
end
point
includ
frequenc
rate
clinic
symptom
fever
rhinorrhea
nasal
congest
sore
throat
cough
sputum
dyspnea
diarrhea
nausea
vomit
headach
myalgia
symptom
durat
sever
symptom
total
symptom
score
assess
conduct
telephon
weekli
selfreport
intervent
period
symptom
score
averag
rang
subject
ask
complet
daili
log
time
everi
morn
document
sever
influenzarel
symptom
scale
sheet
symptom
mild
symptom
moder
symptom
sever
symptom
total
number
day
symptom
calcul
telephon
interview
everi
day
symptom
disappear
safeti
assess
case
advers
event
includ
laboratori
test
hematolog
biochemistri
urinalysi
vital
sign
assess
systol
blood
pressur
diastol
blood
pressur
puls
rate
statist
analysi
done
statistician
blind
condit
efficaci
analysi
done
subject
complet
studi
per
protocol
pp
group
wherea
frequenc
rate
ari
done
use
fisher
exact
test
symptom
durat
score
analyz
mann
whitney
u
test
fisher
exact
test
safeti
assess
also
done
subject
complet
studi
per
protocol
pp
group
analysi
two
group
done
use
mann
whitney
u
test
fisher
exact
test
use
repeat
measur
analysi
varianc
anova
compar
laboratori
find
two
group
clinic
trial
spss
softwar
ver
spss
inc
chicago
il
usa
use
analys
p
valu
less
consid
statist
signific
subject
gave
written
inform
consent
enter
studi
conduct
accord
intern
confer
harmon
guidelin
good
clinic
practic
approv
function
food
institut
review
board
chonbuk
nation
univers
hospit
irb
number
ijrginflkrg
screen
total
subject
enrol
studi
randomli
assign
krg
placebo
group
male
femal
studi
period
subject
fail
complet
studi
krg
placebo
fig
mean
age
subject
yr
old
krg
group
placebo
p
signific
differ
gener
characterist
studi
popul
two
group
tabl
alcohol
smoke
frequent
krg
group
signific
differ
two
group
p
p
total
number
prescrib
capsul
p
total
intak
p
signific
two
group
complianc
report
take
medic
high
group
krg
placebo
group
subject
fail
complet
studi
due
complianc
tabl
blind
also
maintain
adequ
studi
period
studi
take
krg
take
placebo
thought
given
krg
studi
period
subject
experienc
ari
least
one
time
total
tabl
krg
placebo
respect
frequenc
ari
krg
group
lower
placebo
group
find
statist
signific
p
studi
absolut
risk
reduct
absolut
rate
differ
two
group
confid
interv
ci
rel
risk
reduct
mean
give
krg
reduc
ari
ci
among
subject
experienc
ari
symptom
durat
day
krg
group
day
placebo
group
p
symptom
durat
krg
group
short
statist
differ
two
group
tabl
symptom
score
krg
vs
placebo
lower
krg
group
placebo
group
howev
statist
signific
observ
p
among
symptom
frequenc
rate
cough
p
krg
group
significantli
lower
placebo
group
nasal
congest
p
headach
p
krg
group
lower
placebo
group
margin
signific
statist
differ
two
group
advers
event
specif
sever
advers
event
observ
studi
period
p
tabl
laboratori
find
safeti
includ
hematolog
biochemistri
urinalysi
statist
differ
two
group
tabl
supplementari
medic
particulari
nsaid
use
subject
krg
placebo
group
respect
p
antibiot
placebo
vs
krg
vs
p
antihistamin
placebo
vs
krg
vs
p
use
cold
flu
respect
differ
inci
denc
nsaid
usag
two
group
found
statist
signific
incid
antibiot
usag
margin
common
placebo
krg
group
antihistamin
usag
significantli
common
placebo
krg
group
frequenc
rate
ari
significantli
lower
krg
group
placebo
group
studi
symptom
durat
short
symptom
score
lower
krg
group
placebo
group
howev
statist
signific
observ
regard
safeti
krg
specif
clinic
laboratori
side
effect
week
healthi
subject
process
steam
dri
manufactur
red
ginseng
occur
variou
chemic
reaction
eventu
lead
product
effect
compon
found
fresh
ginseng
also
effect
absorpt
digest
variou
activ
compound
consid
strength
red
ginseng
red
ginseng
shown
variou
immunomodulatori
action
activ
natur
killer
cell
inhibitori
action
food
allergi
antagonist
reaction
immunosuppress
agent
activ
innat
immun
proven
broad
rang
biolog
activ
includ
tcell
mediat
immun
reaction
well
antioxid
antitumor
action
recent
kim
et
al
report
effect
oral
administr
krg
influenza
viru
infect
studi
investig
inhibitori
effect
krg
extract
plaqu
format
influenza
viru
cellbas
plaqu
assay
effect
oral
administ
krg
influenza
viru
infect
mice
suggest
krg
could
potenti
use
complementari
treatment
influenza
viru
kaneko
nakanishi
variabl
present
number
percentag
mean
sd
analyz
mann
whitney
u
test
chisquar
test
fisher
exact
test
durat
score
symptom
calcul
sum
symptom
variabl
present
number
percentag
mean
sd
analyz
repeat
measur
anova
p
valu
mean
signific
level
krg
group
placebo
group
wbc
white
blood
cell
rbc
red
blood
cell
plt
platelet
alp
alkalin
phosphatas
ast
aspart
transaminas
alt
alanin
transaminas
gt
gamma
glutamyl
transferas
bun
blood
urea
nitrogen
hpf
high
power
field
perform
retrospect
studi
long
term
use
krg
staff
geriatr
hospit
also
report
krg
prevent
effect
common
cold
symptom
complex
includ
flu
howev
well
design
clinic
trial
regard
effect
ari
krg
mcelbaney
et
al
compar
american
ginseng
placebo
prevent
acut
respiratori
ill
institut
set
influenza
season
studi
mean
age
volunt
yr
old
femal
approxim
receiv
influenza
vaccin
yr
confirm
viral
acut
respiratori
ill
conduct
cultur
serolog
influenza
show
incid
laboratori
confirm
influenza
ill
lower
american
ginseng
group
placebo
group
odd
ratio
ci
combin
data
laboratori
confirm
influenza
ill
respiratori
syncyti
viru
ill
ci
also
lower
american
ginseng
studi
group
placebo
group
suggest
american
ginseng
potenti
effect
prevent
acut
respiratori
ill
predi
et
al
perform
clinic
trial
similar
studi
mean
age
volunt
femal
subject
exclud
vaccin
influenza
previou
month
mean
number
cold
per
person
lower
ginseng
group
placebo
group
ginseng
vs
placebo
vs
ci
proport
subject
jacksonverifi
cold
ginseng
vs
placebo
vs
p
significantli
lower
ginseng
group
placebo
group
total
symptom
score
ginseng
vs
placebo
vs
p
total
number
day
cold
symptom
report
ginseng
vs
placebo
vs
p
result
show
american
ginseng
protect
effect
ari
howev
effect
krg
ari
studi
although
known
broad
rang
biolog
activ
effect
krg
influenza
viru
infect
studi
show
krg
signific
protect
effect
ari
decreas
symptom
durat
symptom
score
similar
american
ginseng
herbal
medicin
togeth
declin
number
new
antimicrobi
certifi
introduc
clinic
practic
one
fastest
grow
altern
therapi
use
herbal
medic
rang
treatment
prevent
common
ill
cancer
treatment
prevent
herbal
medicin
dietari
supplement
appear
safe
medic
literatur
support
effect
certain
condit
one
well
studi
herbal
medicin
krg
broad
rang
activ
well
protect
effect
ari
henc
potenti
effect
combat
differ
emerg
strain
viru
studi
antihistamin
antibiot
use
frequent
placebo
group
compar
krg
group
sever
limit
studi
first
calcul
number
subject
statist
preliminari
studi
need
extens
clinic
studi
clear
statist
number
second
conduct
microbiolog
analysi
ari
therefor
certain
natur
viru
number
strain
third
includ
healthi
volunt
without
influenza
vaccin
clinic
trial
healthi
volunt
influenza
vaccin
vs
without
vaccin
variou
age
group
requir
conclus
krg
protect
effect
contract
ari
may
tendenc
decreas
durat
score
ari
symptom
howev
need
studi
statist
power
subject
children
vaccin
subject
immuonocompromis
subject
